pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 28·1 min read
save

Devoted Health reports first revenue decline in 2025 amid Medicare Advantage turbulence

Apr 28, 2026·read at Endpoints ↗Negative

Devoted Health, a startup offering Medicare Advantage plans, saw its revenue and membership drop in 2025, marking the first decline since it began offering plans seven years ago.

The downturn reflects broader challenges in the Medicare Advantage market, which has become more competitive and faces pricing pressures.

The company, led by former Athenahealth executives, may need to adjust its strategy to regain growth, though no specific actions were detailed.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Devoted Health’s 2025 revenue slips in turbulent Medicare Advantage market”

read at Endpoints ↗
83 words · retrieved Apr 29
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 10h agoFormer MIT professor David Sabatini awarded $6M in defamation caseEndpoints
  • 11h agoAntheia gets $80M conditional DOD loan to onshore to the USEndpoints
  • 13h ago#ESMO26 regular abstracts featuring Zai Lab, GSK, Merck and moreEndpoints
  • 15h agoGilead’s pill posts stronger colitis remission rates than EntyvioEndpoints
  • 15h agoEyePoint's Phase 3 failure; Lilly's China drug delivery dealEndpoints